Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Conjugate vaccine is a combination of a weak antigen with a strong antigen so to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.
Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria.
Market Dynamics
Increasing cases of infectious diseases such as typhoid, pneumonia, and others is expected to drive the global conjugate vaccine growth. For instance, according to a study published in Science Direct Journal in 2021, 11.9 – 26.9 million cases of typhoid fever occur each year in low- and middle-income countries (LMICs) Moreover, as per the WHO 2016 data, around one million children globally die from pneumonia every year and there has been an increasing demand for safe and effective vaccines that could prevent these deaths.
Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.
This app enables healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.
However, there are some challenges in global implementation of protein conjugate polysaccharide vaccines which may hamper the growth of conjugate vaccine market. For instance, according to the NCBI 2014 article, challenges in implementation of conjugate vaccines includes replacement by nonvaccine serotypes, capsule switching, time duration of the antibody protective effect following vaccination, cost of the vaccines, program costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.
Key features of the study:
This report provides in-depth analysis of the global conjugate vaccine market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global conjugate vaccine market based on the following parameters – company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global conjugate vaccine market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global conjugate vaccine market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Conjugate vaccine market, By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
Global Conjugate vaccine market, By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
Global Conjugate vaccine market, By Pathogen Type:
Bacterial
Viral
Global Conjugate vaccine market, By Patients Type:
Pediatric
Adults
Global Conjugate vaccine market, By Region:
North America
By Country:
U.S.
Canada
By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
By Pathogen Type:
Bacterial
Viral
By Patients Type:
Pediatric
Adults
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
By Pathogen Type:
Bacterial
Viral
By Patients Type:
Pediatric
Adults
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
By Pathogen Type:
Bacterial
Viral
By Patients Type :
Pediatric
Adults
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
By Pathogen Type:
Bacterial
Viral
By Patients Type :
Pediatric
Adults
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
By Pathogen Type:
Bacterial
Viral
By Patients Type :
Pediatric
Adults
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
By Pathogen Type:
Bacterial
Viral
By Patients Type :
Pediatric
Adults
Company Profiles
Sanofi S.A *
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Pfizer, Inc.
Merck & Co., Inc.
GlaxoSmithKline plc
Bharat Biotech.
Serum institute of India Pvt. Ltd.
Biological E. Limited
Bio-Med
“*” marked represents similar segmentation in other categories in the respective section.